Literature DB >> 2322425

Acute bone marrow aplasia associated with intravenous administration of deferoxamine (desferrioxamine).

K Sofroniadou1, M Drossou, L Foundoulaki, K Konstantopoulos, D Kyriakoy, J Zervas.   

Abstract

The authors report the clinical course and fatal outcome of a case of acute bone marrow aplasia, after intravenous administration of deferoxamine (desferrioxamine) to a 16-year-old girl with homozygous beta-thalassaemia. The type of aplasia was mainly that of a megakaryocytic thrombocytopenia, but the 2 other haemopoetic series were also involved. The absence of any other toxic factors and the quite rapid onset of the bone marrow failure after this type of treatment strongly suggest that intravenous administration of high doses of deferoxamine was the potential toxic factor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2322425     DOI: 10.2165/00002018-199005020-00005

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  4 in total

1.  High-dose desferrioxamine as a cause of growth failure in thalassemic patients.

Authors:  A Piga; L Luzzatto; P Capalbo; S Gambotto; F Tricta; V Gabutti
Journal:  Eur J Haematol       Date:  1988-04       Impact factor: 2.997

2.  Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia.

Authors:  S De Virgiliis; M Congia; M P Turco; F Frau; C Dessi; F Argiolu; R Sorcinelli; A Sitzia; A Cao
Journal:  Arch Dis Child       Date:  1988-03       Impact factor: 3.791

3.  Thrombocytopenia associated with intravenous desferrioxamine.

Authors:  J A Walker; R A Sherman; R P Eisinger
Journal:  Am J Kidney Dis       Date:  1985-10       Impact factor: 8.860

4.  Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions.

Authors:  N F Olivieri; J R Buncic; E Chew; T Gallant; R V Harrison; N Keenan; W Logan; D Mitchell; G Ricci; B Skarf
Journal:  N Engl J Med       Date:  1986-04-03       Impact factor: 91.245

  4 in total
  3 in total

Review 1.  World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

Authors:  Christina N Kontoghiorghe; Nicholas Andreou; Katerina Constantinou; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2014-09-26

Review 2.  Deferoxamine (desferrioxamine). New toxicities for an old drug.

Authors:  Y Bentur; M McGuigan; G Koren
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

Review 3.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.